ALLK News and Press, Allakos Inc.

2024-06-26 14:34:42 ET More on Allakos Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Financial information for Allakos Read the full article on Seeking Alpha For further details see: Allakos drops after early-...

– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was well-tolerated with a favorable safety pro...

– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chr...

2024-05-09 18:08:15 ET More on Allakos Seeking Alpha’s Quant Rating on Allakos Historical earnings data for Allakos Read the full article on Seeking Alpha For further details see: Allakos GAAP EPS of -$0.81 misses by $0.37

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for...

2024-04-09 06:31:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason. Most biotech companies fail, as their success often h...

2024-03-14 17:13:45 ET More on Allakos Allakos extends losses as analysts downgrade on Phase 2 setback Read the full article on Seeking Alpha For further details see: Allakos GAAP EPS of -$0.71 misses by $0.20

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results f...

Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...

Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...